 | ||
 | ||
 |
Press ReleasesNobilon advances intranasal seasonal influenza vaccine into proof of concept studyBOXMEER (The Netherlands), October 13, 2009 - Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
Nobilon advances first vaccine into human trials - Intranasal influenza vaccine begins PHASE I Clinical DevelopmentBOXMEER (The Netherlands), March 12, 2009 – Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
Schering-Plough announces collaboration with World Health Organization to provide access to pandemic influenza vaccine technology to developing countriesKENILWORTH, N.J. and BOXMEER, The Netherlands, Feb. 23, 2009 – Schering-Plough Corporation (NYSE: SGP) today announced a license agreement between Nobilon, Schering-Plough’s human vaccine business unit, and the World Health Organization (WHO) to provide access to pandemic influenza vaccine manufacturing technology to developing countries.
European expert consortium combines forces to develop a novel pandemic influenza vaccineA consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of €3.5 million from the European Union to help fund the research and the development of the new vaccine. The so-called FluVac project will be coordinated by Nobilon International BV which is part of Organon, the human healthcare business unit of Akzo Nobel.
Protherics licenses its CoVaccine HT adjuvant to Nobilon for influenza vaccine indicationsNobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT™ adjuvant for use in pandemic influenza vaccines, and seasonal influenza vaccines in elderly people.
Nobilon acquires rights to EBx™ cell lines from Vivalis for development, production and marketing of influenza vaccinesNobilon and Vivalis announced today that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human influenza vaccines, including seasonal and pandemic.
Nobilon, BioDiem and leading U.S. scientists developing pandemic avian flu vaccineScientists at Akzo Nobel's Nobilon International human vaccines business working to fight the threat of a global bird flu pandemic have received a major boost following the signing of a cooperative research and development agreement with the Centers for Disease Control and Prevention (CDC) in the United States.
Nobilon and NVI co-developing RSV vaccineNobilon has signed a contract with the Netherlands Vaccine Institute (NVI) to jointly develop a vaccine against respiratory syncytial virus (RSV)
Nobilon and CoroNovative join forces in virus discovery programNobilon is to work together with the Dutch Erasmus Medical Center’s spin-off, CoroNovative BV, to expand and accelerate CoroNovative’s virus discovery program. |
Press release
|
| Our company | Sitemap |
| Home | Disclaimer | Privacy | Contact |